Mounjaro, a weight-loss injection, has been linked to panic attacks and anxiety among users, raising safety concerns.
Topics covered
Women across the UK are experiencing distressing mental health side effects after using Mounjaro, a weight-loss injection that has gained significant popularity. Reports of sudden panic attacks, crippling anxiety, and unsettling sensations in the brain have surfaced, raising urgent questions about the safety of this medication.
The rise of Mounjaro
Since its launch, Mounjaro has been marketed as a revolutionary solution in the battle against obesity. Alongside other treatments like Ozempic and Wegovy, it promises substantial weight loss—up to 15% of body weight within a year.
By March 2025, an astonishing 1.5 million Britons had already turned to weight-loss jabs, believing they found a breakthrough in managing their weight.
Unexpected fallout
However, as more users share their experiences, a disturbing pattern emerges. While the injections boast physical benefits, numerous patients are reporting severe mental health symptoms, including insomnia, tremors, and even shortness of breath. These alarming effects are not listed as official side effects for any of the major injections in the UK, yet a growing online support group has quickly attracted over 2,800 members sharing their struggles.
Real experiences, real fear
Among the voices raising concerns is Charlotte Lloyd, a 37-year-old social media manager from London. After taking Mounjaro, she found herself in A&E, grappling with anxiety so intense it felt like terror. “The anxiety was something I had never experienced before,” she confessed. Charlotte’s ordeal began soon after her first dose; a loss of appetite was quickly followed by sleepless nights. By the time she took her second dose, she was already spiraling into despair, unable to find relief through sleeping pills or other methods.
A heart-pounding reality
For Charlotte, the symptoms escalated to the point where she experienced a racing heart, leading her to the hospital. An ECG showed her heart rate was elevated, but no irregularities were detected. “They told me to go home and have a bath,” she recounted, still struggling to cope with her sleeplessness and anxiety. Despite acknowledging her previous history of anxiety, the medication was approved without further scrutiny.
Wider implications
The situation has sparked renewed scrutiny over Mounjaro’s safety profile. As reports of psychological side effects accumulate, the question arises: are these medications too risky for widespread use? Another woman, Maria Edwards, found herself in a similar predicament. Within just 48 hours of her first Mounjaro dose, she believed she was having a heart attack. “I’ve never had any mental health problems before this,” she shared, expressing regret for not being warned about potential side effects.
Voices of concern
Julie Peters, a 31-year-old mother, also faced a panic attack after starting Mounjaro. Her experience mirrored that of many others—tests revealed no underlying health issues, leaving her to grapple with a whirlwind of symptoms that felt suffocating. “I feel disconnected and nauseous, and I’ve developed a sensitivity to motion,” she explained, highlighting the intense pressure she felt in her head. Despite normal MRI results, Julie remains uncertain about her next steps.
Research and oversight
These troubling accounts echo findings from a recent study published in the International Journal of Clinical Pharmacy, which linked 481 psychiatric events to weight-loss medications. Although these cases represent a small fraction of overall reports, they reveal a crucial need for further research into the causal relationships between these drugs and mental health outcomes.
Industry responses
Neither Asda Online Doctor nor the patient information leaflets highlight anxiety or depression as potential side effects, leading to questions about the transparency of drug information provided to patients. The clinical governance team emphasizes the importance of thorough medical history reviews, but critics argue that more robust safeguards are needed before prescribing such powerful medications.
Future considerations
Amidst the rising tide of complaints, the manufacturers of Mounjaro and similar drugs assert that patient safety is their top priority. Eli Lilly and Novo Nordisk have expressed a commitment to monitoring safety reports closely. Yet with increasing evidence suggesting that these medications may not be as safe as once thought, the need for independent research and patient awareness has never been more pressing.
As this story develops, the impact of Mounjaro and its counterparts on mental health continues to unfold. What remains uncertain is the broader implications for those seeking help in their weight-loss journeys. With so many lives impacted, will these medications truly be the solution to obesity, or are we facing a hidden crisis?
